CB-13 (CRA13, SAB-378) [1] is a cannabinoid drug, which acts as a potent agonist at both the CB 1 and CB 2 receptors, but has poor blood–brain barrier penetration, and so produces only …

Aug 8, 2022 · We evaluated the impact of repeated administration of CB-13 on therapeutic tolerance in CFA-treated animals and on the cannabinoid behavior “triad” (catalepsy, …

Aug 1, 2022 · In the present study, we evaluated the effects of acute and repeated dosing with the peripherally selective CB 1 -preferring agonist CB-13 on nociception and central CB 1 -related …

3.1 NUCLEAR MAGNETIC RESONANCE Sample Preparation: Dilute analyte to ~22 mg/mL in deuterochloroform ( CDCl3) containing TMS for 0 ppm reference and dimethylsulfone as …

CB-13 reduced inflammation-induced mechanical allodynia in male and female mice in a peripheral CB 1 -receptor-dependent manner and relieved inflammatory thermal hyperalgesia.

CB-13: A dual agonist of the CB₁ and CB₂ receptors. CAS Number: 432047-72-8. Synonym: CRA-13. Purity: ≥98%.

In the present study, we evaluated the effects of acute and repeated dosing with the peripherally selective CB 1 -preferring agonist CB-13 on nociception and central CB 1 -related phenotypes …

CB-13 is a cannabinoid drug, which acts as a potent agonist at both the CB1 and CB2 receptors, but has poor blood-brain barrier penetration, and so produces only peripheral effects at low …

CB-13 (CRA13, SAB-378) is a cannabinoid drug, which acts as a potent agonist at both the CB 1 and CB 2 receptors, but has poor blood–brain barrier penetration, and so produces only …

Apr 23, 2024 · As a potent and selective agonist for the CB1 receptor, CB-13 stands out in the realm of cannabinoid research for its unique chemical structure and pharmacological …